

MayoComplete Kidney Cancer Panel, Next-
Generation Sequencing, Tumor

Patient ID SA00174994	Patient Name TESTINGRNV, NORMAL	Birth Date 1959-02-04	Sex M	Age 66
Order Number SA00174994	Client Order Number SA00174994	Ordering Physician CLIENT,CLIENT	Report Notes	
Account Information C7028846 DLMP Rochester		Collected 28 Mar 2025 00:00		

MayoComplete Kidney Cancer Panel

Result

MCR

Provided diagnosis: kidney renal cell carcinoma

Microsatellite Instability (MSI) status: Stable (MSS)

No reportable sequence variants were detected within the analyzed regions of the tested genes listed in the method description.

Interpretation

MCR

No clinically significant gene mutations informative for diagnosis, prognosis or predictive of response to therapy were identified within the analyzed genes. Test results should be interpreted in the context of clinical findings, tumor sampling, histopathology, and other laboratory data. If results obtained do not match other clinical or laboratory findings, please contact the laboratory.

An abnormality involving the genes evaluated in this panel is not excluded since sequence variants and fusions/transcript variants involving non-targeted gene regions, and genomic abnormalities not detectable by this method (e.g. genomic copy number alterations, epigenetic changes) may be present. If not already performed, consider chromosomal microarray analysis to assess for copy number changes (CMAP/ Chromosomal Microarray, Tumor, FFPE).

MSI: Stable (MSS)

NO evidence of microsatellite instability was detected suggesting the presence of normal DNA mismatch repair function within the tumor. Current data suggest that advanced stage solid tumors with intact mismatch repair (MSS) are less likely to be responsive to treatment with immunotherapies such as anti-PD-1 therapies [PMID 28596308, PMID 29355075].

Additional Information

MCR

CLINICAL TRIALS

Possible clinical trials of benefit for this patient can be found at the following sites:

1) ClinicalTrials.gov:

www.clinicaltrials.gov/ct2/search/advanced

2) Mayo Clinic: www.mayo.edu/research/clinical-trials/ 3) National Cancer Institute: www.cancer.gov/clinicaltrials/search

Specimen

MCR

Tissue, Tumor

Tissue ID

MCR

13245

Method

MCR

Microscopic examination is performed by a pathologist to identify areas of tumor for enrichment by macrodissection.

Next generation sequencing is performed to test for the presence of microsatellite instability and a mutation within most coding regions and exon/intron boundaries of the following genes: ATRX, BAP1, BRAF, CDKN2A, ELOC, FH, FLCN, KRAS, MET, MITF, MTOR, MLH1, MSH2, MSH6, NF2, PBRM1, PMS2, PTEN, RB1, SDHA, SDHB, SDHC, SDHD, SETD2, SMARCB1, TERT, TP53, TSC1, TSC2, and VHL

Variant nomenclature is based on build GRCh37 (hg19). For details about gene transcripts (RefSeq accession numbers), specific targeted regions of each gene, and additional information on this test, see www.mayocliniclabs.com (Test ID MCKCP).

Disclaimer

1 MCR

This test cannot differentiate between somatic and germline alterations. Additional testing may be necessary to clarify the significance of results if there is a potential hereditary risk.

Performing Site Legend

Code	Laboratory	Address	Lab Director	CLIA Certificate
MCR	Mayo Clinic Laboratories - Rochester Main Campus	200 First Street SW, Rochester, MN 55905	Nikola Baumann Ph.D.	24D0404292

Patient ID SA00174994	Patient Name TESTINGRNV, NORMAL	Birth Date 1959-02-04	Sex M	Age 66
Order Number SA00174994	Client Order Number SA00174994	Ordering Physician CLIENT,CLIENT	Report Notes	
Account Information C7028846 DLMP Rochester		Collected 28 Mar 2025 00:00		

DNA variants of uncertain significance may be identified.

A negative result does not rule out the presence of a variant that may be present but below the limits of detection of this assay. The analytical sensitivity of this assay for sequence reportable alterations is 5% mutant allele frequency with a minimum coverage of 500X in a sample with at least 20% tumor content.

Point mutations and small insertion/deletion mutations will be detected in the ATRX, BAP1, BRAF, CDKN2A, ELOC, FH, FLCN, KRAS, MET, MITF, MTOR, MLH1, MSH2, MSH6, NF2, PBRM1, PMS2, PTEN, RB1, SDHA, SDHB, SDHC, SDHD, SETD2, SMARCB1, TERT, TP53, TSC1, TSC2, and VHL genes only. This test may detect single exon deletions but does not detect multi-exon deletions, duplications, larger-scale genomic copy number variants, copy neutral loss of heterozygosity (LOH), or epigenetic modifications such as promoter methylation. DELINS of 1,000 bp or less are detectable with at least 50 or more supporting reads.

This test cannot reliably determine if a variant identified in PMS2 exons 11–15 originated from PMS2 or the highly homologous pseudogene PMS2CL. In the instance that a reportable variant is detected in PMS2 exons 11–15, additional testing will be recommended in the patient report.

Variant allele frequency (VAF) is the percentage of sequencing reads supporting a specific variant divided by the total sequencing reads at that position. In somatic testing, VAF should be interpreted in the context of several factors including, but not

limited to: tumor purity/heterogeneity/copy number status (ploidy, gains/losses, loss of heterozygosity) and sequencing artifact/misalignment [PMID: 27144058, PMID: 29769535].

Rare polymorphisms may be present that could lead to false-negative or false-positive results.

The presence or absence of a variant may not be predictive of response to therapy in all patients.

Test results should be interpreted in the context of clinical, tumor sampling, histopathological, and other laboratory data. If results obtained do not match other clinical or laboratory findings, contact the laboratory for discussion. Misinterpretation of results may occur if the information provided is inaccurate and/or incomplete.

Reliable results are dependent on adequate specimen collection and processing. This test has been validated on cytology slides and formalin-fixed, paraffin-embedded tissues; other types of fixatives are discouraged. Improper treatment of tissues, such as decalcification, may cause PCR failure.

Released By

MCR

Ying-Chun Lo, M.D., Ph.D.

Received: 29 Mar 2025 15:17

Reported: 07 Apr 2025 17:11

Laboratory Notes

- ① This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

Performing Site Legend

Code	Laboratory	Address	Lab Director	CLIA Certificate
MCR	Mayo Clinic Laboratories - Rochester Main Campus	200 First Street SW, Rochester, MN 55905	Nikola Baumann Ph.D.	24D0404292